Lilly's Q2 2026 revenue rose 48%; revenue guidance raised to $85B-$87B

Eli Lilly reported second-quarter 2026 revenue of $23.0 billion, up 48%, with Mounjaro up 91% and Zepbound up 46%. It raised 2026 revenue guidance to $85 billion-$87 billion, but its non-GAAP EPS guidance moved to $35.50-$36.50 because $3.03 per share of acquired IPR&D charges more than offset the underlying EPS increase. Retatrutide's obesity data package is now complete ahead of a Q1 2027 filing.

• Q2 2026 revenue $22,974M, up 48%
• Mounjaro $9,943M (up 91%); Zepbound $4,928M (up 46%)
• Reported EPS $7.94; non-GAAP EPS $8.38, after $3.03 per share of acquired IPR&D charges
• 2026 guidance: revenue $85B-$87B; non-GAAP EPS $35.50-$36.50